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Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is the requisite precursor
to multiple myeloma (MM), a malignancy of antibody-producing plasma B-cells. The genetic
basis of MGUS and its progression to MM remains poorly understood. C57BL/KaLwRij
(KaLwRij) is a spontaneously-derived inbred mouse strain with a high frequency of benign
idiopathic paraproteinemia (BIP), a phenotype with similarities to MGUS including progres-
sion to MM. Using mouse haplotype analysis, human MM SNP array data, and whole
exome and whole genome sequencing of KaLwRij mice, we identified novel KaLwRij gene
variants, including deletion of Samsn1 and deleterious point mutations in Tnfrsf22 and
Tnfrsf23. These variants significantly affected multiple cell types implicated in MM patho-
genesis including B-cells, macrophages, and bone marrow stromal cells. These data dem-
onstrate that multiple cell types contribute to MM development prior to the acquisition of
somatic driver mutations in KaLwRij mice, and suggest that MMmay an inherently non-cell
autonomous malignancy.
Introduction
Multiple myeloma (MM) is the second most common hematological malignancy and is charac-
terized by accumulation of clonal plasma B-cells in the bone marrow, hypercalcemia, renal fail-
ure, anemia, and lytic bone lesions. Despite impressive recent progress in treatments for MM,
median survival is only 6 years [1]. The requisite precursor to MM is monoclonal gammopathy
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of undetermined significance (MGUS), a pre-neoplastic proliferation of clonally derived plas-
ma cells without end organ damage.
Epidemiological studies suggest a genetic component to MM disease risk that is due to an
increase MGUS development. African Americans have an increased risk of MM due to elevated
MGUS risk, rather than an increased rate of conversion fromMGUS to overt MM [2–4]. More-
over, inherited risk variants for MM also confer a significant increase in risk for MGUS [5],
providing further evidence that increased MM susceptibility is due to inherited predisposition
to MGUS. Interestingly, the somatic mutations responsible for disease progression from
MGUS to MM remain unknown. The majority of somatic mutations found in CD138-selected
MM cells are present at similar frequencies in similar cells isolated from MGUS patients [6],
suggesting that plasma-cell extrinsic factors may contribute to disease progression in MM.
Few experimental models exist to study the biology of MGUS and MM in a laboratory set-
ting, confounding efforts to understand the biology of MM progression. Xenograft models to
study human myeloma growth, e.g. SCID-hu, require the presence of a human bone marrow
microenvironment [7], highlighting the importance of non-malignant cells within the
myeloma microenvironment.
The C57BL/KaLwRij mouse (KaLwRij) is a spontaneously-derived inbred mouse strain
identified nearly 40 years ago that is predisposed to myeloma [8]. KaLwRij mice develop be-
nign idiopathic paraproteinemia (BIP), a condition analogous to human MGUS, at a high rate.
Affected mice progress to myeloma at the same low rate as humans do, approximately 1% per
year. The 5TGM1 cell line originally isolated from a sick KaLwRij mouse is often used as a
model of myeloma because when transplanted back into KaLwRij mice, it causes disease with
similar clinical features as human MM including lytic bone lesions [8]. Notably, while the
5TGM1/KaLwRij model recapitulates many features of human disease, the genetic basis of BIP
susceptibility in KaLwRij mice remains unknown.
In this study, we investigated the genetic determinants underlying the BIP predisposition of
the KaLwRij strain. Using an integrative genetics approach, including whole genome and
exome sequencing, we identified novel KaLwRij gene variants, such as homozygous deletion of
Samsn1 and deleterious point mutations in tumor necrosis factor receptor family members.
KaLwRij genetic variants significantly affected multiple cell types implicated in MM pathogen-
esis including B-cells, macrophages, and bone marrow stromal cells. These results illuminate
pathways responsible for MM disease risk, and demonstrate for the first time that the develop-
ment of myeloma involves multiple cell types prior to the acquisition of somatic mutations.
Results
Wemapped genetic distances among myeloma-prone KaLwRij and eleven diverse inbred
mouse strains using SNP arrays. KaLwRij was most closely related to its parent strain C57BL/6
(Fig 1A). Initially we hypothesized that KaLwRij predisposition to BIP would be reflected in a
unique antibody response to immune challenge and that sustained serum immunoglobulin lev-
els would provide a measurable quantitative phenotype to perform quantitative trait loci
(QTL) mapping. Following immunization of these twelve strains (S1A Fig), analysis of serial
serum samples by immunoglobulin ELISA demonstrated that the antibody response was highly
heritable (IgG h2 = 0.7247, IgM h2 = 0.9551, IgA h2 = 1.019), indicating influence by genetic
background (S1B–S1D Fig). Serum protein electrophoresis (SPEP), a standard diagnostic test
for human MGUS, was used to identify M-spikes indicative of BIP (S1E Fig). Most strains pre-
sented with an M-spike immediately following immunization, indicating a normal immune re-
sponse (S1 Table). M-spike presentation may be due either to increased survival of plasma cells
or increased activation of memory B-cells, but work beyond the scope of this manuscript is
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Fig 1. The KaLwRij strain was predisposed to BIP and intersecting mouse and human genetic analyses identified candidate genes that may
influencemurine BIP risk and humanMM risk. (a) Phylogenetic tree demonstrating genetic distances of 12 inbred strains of mice. (b) Number of C57BL/6
and KaLwRij mice with positive M-spike by SPEP. (c) Haplotype analysis identified contiguous regions of non-shared polymorphic alleles between KaLwRij
and C57BL/6 mice (red bars) in 419 genes. (D) GWAS between MM patients and healthy volunteers. SNPs in the 99th percentile (dashed line) fell in 178
genes. (e) Venn diagram representing combined analysis of (c) and (d), resulting in a candidate gene list of 5 genes.
doi:10.1371/journal.pone.0127828.g001
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necessary to dissect these possibilities. The highest frequency of an abnormal M-spike sus-
tained to 18 months was found in KaLwRij (56%) while it had resolved in C57BL/6 mice (Fig
1B). The 18-month time frame and qualitative nature of the BIP phenotype prevented us from
further pursuing QTL mapping.
We took advantage of the close genetic distance between BIP-resistant C57BL/6 and BIP-
susceptible KaLwRij mouse strains to use haplotype mapping to identify BIP candidate genes.
Of 562,061 single nucleotide polymorphisms (SNPs) queried, 21,133 SNPs varied between
KaLwRij and C57BL/6 (3.76%). A ranked list, defined by blocks of five or greater physically
consecutive divergent SNPs, identified 418 candidate genes different between C57BL/6 and
KaLwRij (Fig 1C, S2 Table). To enrich for candidate genes relevant to human MM, we took an
integrative cross-species approach. We performed genome-wide association analysis (GWAS)
on genomic DNA isolated from normal tissue of 305 MM patients and 353 healthy controls to
identify common genetic variants associated with MM. The relatively small patient population
identified only one SNP (rs1029654 in an intergenic region) that reached genome-wide signifi-
cance. To include additional genetic variants associated with MM risk, we queried SNPs in the
99th significance percentile (209 SNPs, Fig 1D) and generated a candidate gene list of 177
genes possibly influencing MM risk in humans (S3 Table). Importantly, this approach identi-
fied SNPs in three of the seven previously published genetic loci associated with MGUS and
MM risk (2p23.3, 3p22.1, and 7p15.3), validating our approach. The intersection of the KaL-
wRij and C57BL/6 haplotype gene set (418 genes) and the human GWAS set (177 genes) con-
tained five genes: Fstl4, Samsn1, Ccm2, Tenm3, and Csmd1 (Fig 1E).
To characterize these loci at base-pair resolution and to identify additional genomic variants
contributing to MM pathogenesis, we performed whole genome sequencing (WGS) and whole
exome sequencing (WES). 926,326,580 reads were obtained by WGS and 75,950,592 by WES,
with 96.0% and 98.9% mapping to the reference C57BL/6 genome respectively. These data
were analyzed for large deletions, single nucleotide variants (SNVs), and small insertion or de-
letion events (S4–S7 Tables). 19,042 cross-validated SNVs were identified in the KaLwRij ge-
nome (S5 Table and data not shown). Of these SNVs, 1,128 (5.9%) resulted in non-
synonymous coding sequence changes (S5 Table), with 29 novel variants predicted to be dis-
ruptive (Table 1).
Analysis of structural variants identified two deletions. The first, confirmed by PCR and se-
quence analysis, spanned 1.6 kb within Rfpl3s (data not shown). More compelling, however,
was a large 180 kb deletion encompassing the entire Samsn1 gene (Chr16: 75816190–
75996162; Fig 2A, S2A Fig), which was also identified in our cross-species approach.
To characterize the functional effect of Samsn1 deletion, we utilized a genetic mouse model
with targeted deletion of Samsn1 on the C57BL/6 background. Samsn1-/- mice have increased
B-cell proliferation in vitro and increased immunoglobulin response in the weeks following im-
munization in vivo [9]. The 180 kb deletion resulted in an effective Samsn1 knock-out in KaL-
wRij mice, so we predicted KaLwRij mice would display similar B-cell phenotypes observed in
Samsn1-/- mice. Samsn1 was expressed in C57BL/6 but not in KaLwRij ex vivo stimulated
splenic B-cells, confirming the loss of protein expression predicted by gene deletion (Fig 2B).
B-cells isolated from young KaLwRij prior to onset of BIP and myeloma had significantly in-
creased proliferation following stimulation compared to C57BL/6 (Fig 2C). Additionally, KaL-
wRij mice had a significant and progressive elevation in immunoglobulin IgG2b levels
following immunization (Fig 2D).
We next tested whether Samsn1 expression played a role in fully transformed myeloma
cells. The 5TGM1 myeloma cell line, originally isolated from a myeloma-bearing KaLwRij
mouse [10], was confirmed as Samsn1-null (Fig 2E, S2A Fig). Stable re-expression of Samsn1
decreased proliferation of 5TGM1 cells compared to control under both basal and IL-6
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stimulated conditions (Fig 2F). Taken together, these data demonstrate that Samsn1 regulated
B-cell proliferation in non-tumor bearing mice and restrained MM tumor cell growth in part
through a plasma cell intrinsic mechanism.
SAMSN1 (HACS1) was first cloned on the basis of its differential expression in multiple my-
eloma with low expression in human myeloma cell lines [11]. To further investigate whether
SAMSN1 participates in human myeloma, we queried plasma-cell SAMSN1 gene expression in
patient samples. SAMSN1 was expressed at lower levels in both human MGUS and MM cells
compared to normal human plasma cells (S3 Fig), suggesting that plasma-cell intrinsic
SAMSN1may also play a role in human MM progression.
Samsn1 expression was not restricted to the B-cell lineage (S2B Fig), so we hypothesized
that Samsn1might influence MM development via effects on additional cell types in the tumor
stroma. We examined two cell types known to participate in MM pathogenesis: macrophages
(Samsn1 expressors) and bone marrow stromal cells (BMSCs, Samsn1 non-expressors; S2B
Fig). Microarray analysis of BIP-resistant C57BL/6 and BIP-susceptible KaLwRij primary bone
marrow macrophages identified 281 differentially expressed genes (Fig 3A, S8 Table). KaLwRij
macrophages had increased proliferation (Fig 3B) and increased Chi3l3 (1.80 fold), Chi3l1
Table 1. KaLwRij novel germlinemissense, stoploss, and stopgain mutations.
Chr Position (bp) Gene ID Gene Name Variant
2 20861102 Arhgap21 Rho GTPase activating protein 21 c.C3215T:p.T1072I
3 95130195 Scnm1 Sodium channel modiﬁer 1 c.T559C:p.stop187R
4 88403392 Focad Focadhesin c.A4979T:p.N1660I
7 140274118 5830411N06Rik Riken cDNA 5830411N06 gene c.C1033T:p.Q345stop
7 140466879 Olfr533 Olfactory receptor protein 533 c.G677A:p.R226H
7 140466884 Olfr533 Olfactory receptor protein 533 c.C682T:p.R228C
7 140503539 Olfr536 Olfactory receptor protein 536 c.C919T:p.R307C
7 140691588 Olfr45 Olfactory receptor protein 45 c.C682T:p.R228C
7 143643365 Tnfrsf22 Tumor necrosis factor receptor superfamily, member 22 c.A236C:p.Q79P
7 143680034 Tnfrsf23 Tumor necrosis factor receptor superfamily, member 23 c.A206C:p.Q69P
8 53513574 Aga Aspartylglucosaminidase c.C160A:p.L54M
11 3179430 Sﬁ1 Sﬁ1 homolog, spindle assembly associated (yeast) c.G344A:p.W115stop
11 3923487 Tcn2 Transcobalamin 2 c.C858G:p.F286L
11 4075493 Sec14l3 SEC14-like 3 (S. cerevisiae) c.C1016A:p.T339N
11 5144386 Emid1 EMI domain containing 1 c.A124G:p.T42A
11 43490831 C1qtnf2 C1q and tumor necrosis factor related protein 2 c.G379A:p.G127R
11 49294204 Olfr1392 Olfactory receptor protein 1392 c.A882T:p.K294N
11 50833599 Zfp879 Zinc ﬁnger protein 879 c.G410T:p.G137V
11 51007734 Olfr51 Olfactory receptor protein 51 c.C761T:p.A254V
11 51027442 Olfr54 Olfactory receptor protein 54 c.G439T:p.A147S
11 52144841 Olfr1373 Olfactory receptor protein 1373 c.G688A:p.V230M
11 107179035 Nol11 Nucleolar protein 11 c.C988T:p.P330S
13 21423407 Pgbd1 PiggyBac transposable element derived 1 c.C505T:p.Q169stop
16 32753901 Muc4 Mucin 4, cell surface associated c.C3776A:p.T1259N
17 46555608 Srf Serum response factor c.G221T:p.G74V
17 73535535 Galnt14 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14 c.C519A:p.N173K
18 67402164 Tubb6 Tubulin, beta 6 class c.T1132G:p.F378V
X 20853392 Araf v-raf murine sarcoma 3611 viral oncogene homolog c.G632A:p.R211H
X 51130161 Mbnl3 Muscleblind-like 3 (Drosophila) c.C715A:p.Q239K
doi:10.1371/journal.pone.0127828.t001
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(2.48 fold), and Cxcl2 (3.45 fold) expression, transcriptional markers for pro-tumor M2 macro-
phage polarization. Notably, there were no variants identified in these genes in the KaLwRij ge-
nome. Chi3l3 expression was also significantly increased in macrophages isolated from
Samsn1-/- mice, confirming that these macrophage expression changes were due specifically to
Samsn1 deficiency (Fig 3C).
To test the function of Samsn1 in tumor-associated macrophages in vivo, we injected either
wild-type or Samsn1-/- ex vivo polarized M2 macrophages into established 5TGM1 tumors.
Compared to wild-type, Samsn1-/- M2 macrophages significantly increased the growth of mye-
loma tumors (Fig 3D). These findings indicate that Samsn1 regulates a pro-tumor function of
macrophages in the myeloma microenvironment.
Interestingly, microarray analysis of Samsn1-nonexpressing BMSCs from C57Bl/6 and KaL-
wRij also showed many gene expression differences (Fig 4A). Tnfrsf22, Tnfrsf23, and Tnfrsf26,
identified in the WGS (S5 Table), showed lower expression in KaLwRij BMSCs compared to
C57BL/6 (Fig 4B, S8 Table). Consistent with other reports, expression of Adipoq, previously
implicated in MM biology in mice and patients [12], was also significantly reduced in BMSCs
from KaLwRij (Fig 4C). Fstl4, initially identified by our integrative genetics approach, was also
depleted at steady-state levels in BMSCs (Fig 4D).
Discussion
High throughput WGS analyses of human MM cell genomes have revealed striking genetic di-
versity but have failed to clarify the etiology of MM [13, 14]. The spontaneously-derived KaL-
wRij inbred mouse strain is commonly used as a model for MM but the KaLwRij genome has
not previously been sequenced. Here, we present the WGS of the KaLwRij mouse as well as
provide gene expression profiles for MM-supportive macrophages and BMSCs as evidence for
Fig 2. Samsn1 is deleted in KaLwRij and was a negative regulator in B-cells and transformed
myeloma cells. (a) Genome sequence coverage is shown for the Samsn1 locus. Physical distance shown
along the x-axis and the size and location of the region are indicated. Height of the curve represents
accumulated sequencing reads. There are virtually no reads across Samsn1 indicating a total deletion of
this gene. Hspa13 gene 5’ of Samsn1 (shown and labeled) is not affected, and neither are 3’ genes
AK146213 (shown and labeled) or 4930578N18Rik (first two exons shown but not labeled). Samsn1 is
encoded in reverse orientation. (b) Western blot analysis of SAMSN1 in CD43- splenic B-cells from C57BL/
6 or KaLwRij mice stimulated with IL-4 and LPS for 72 hours. (c) CD43- splenic B-cells were stimulated with
IL-4 and LPS for 72 hours and cell number counted pre- and post-stimulation to determine proliferation. (d)
Mice were immunized (arrowheads indicate primary and secondary immunization) and serial serum
samples collected. IgG2b levels were determined by ELISA. (e) Western blot for Samsn1 in parental 5TGM1
cells, control vector cells (5TGM1-vector), and cells overexpressing Samsn1 (5TGM1-SAMSN1). (f)
5TGM1-vector and 5TGM1-SAMSN1 cells were stimulated with IL-6 for 24 hours. Cell proliferation was
measured by BrdU incorporation.
doi:10.1371/journal.pone.0127828.g002
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multiple cell lineages contributing to MM prior to overt disease manifestation. Rather than
being confined to the B-lineage, the presumed cell of origin of MM, our results suggest that ge-
netic susceptibility alleles are expressed in both the pre-malignant B-cell and in supportive host
microenvironment cells.
Combined analysis of loci that contribute to inherited disease risk to both MM in humans
and BIP in mice identified Samsn1 as a likely candidate to influence disease susceptibility. Sur-
prisingly, we discovered that Samsn1 is homozygously deleted in the KaLwRij genome [15].
KaLwRij mice have a similar phenotype to Samsn1-/-mice including increased proliferation of
B-cells in ex vivo culture and elevated IgG levels with age [9], supporting the conclusion that
absence of Samsn1 drives KaLwRij BIP. Samsn1 add-back inhibited proliferation in trans-
formed MM cells suggesting that the gene can play a plasma-cell intrinsic tumor suppressor
role in KaLwRij mice, but we also demonstrated that the absence of Samsn1 in macrophages
also contributes to MM progression, making the role of this pathway more complex.
Most compelling were the non-plasma cell contributions of Samsn1 to MM. The majority of
genetic alterations in MM cells are already present in MGUS plasma cells [6], suggesting that
plasma cell extrinsic factors contribute to the conversion of MGUS to MM. Rather than being
Fig 3. Loss of Samsn1 enhanced pro-tumor macrophage function. (a) Microarray analysis of gene
expression in C57BL/6 and KaLwRij primary bone marrow macrophages. (b) Proliferation of C57BL/6 and
KaLwRij macrophages was measured by MTT assay. (c) Macrophage M2 polarization marker Chi3l3 in bone
marrow macrophages. (d) Wild-type or Samsn1-/-M2macrophages polarized ex vivo were injected directly
into established 5TGM1 tumors and tumor burden was monitored by bidirectional caliper measurement.
doi:10.1371/journal.pone.0127828.g003
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confined to the affected plasma cell, the genetic susceptibility alleles in KaLwRij also are ex-
pressed in supportive host microenvironment cells. Samsn1-null macrophages had increased
M2 macrophage markers and potently increased myeloma tumor growth in vivo. These data
place Samsn1 as an inhibitor of pro-tumorigenic macrophage polarization and as a plasma-cell
extrinsic regulator of MM growth.
Our findings also strongly suggest that gene loci in addition to Samsn1 are likely to be im-
portant to MM pathogenesis in the KaLwRij model. We found significant gene expression dif-
ferences between C57BL/6 and KaLwRij BMSCs, a myeloma-supportive cell type in the tumor
microenvironment that does not express Samsn1 (Fig 4). Through WGS, we identified addi-
tional KaLwRij genes that may explain differences between KaLwRij and C57BL/6 BMSCs. No-
tably, we identified deleterious variation and decreased expression in multiple BMSC-
expressed genes, including Tnfrsf22, Tnfrsf23, and Tnfrsf26. These genes encode decoy recep-
tors for the TRAIL cytokine [16]. TRAIL-OPG signaling has been implicated in MM progres-
sion in humans [17], and these KaLwRij variants may support MM via paracrine signaling.
WGS also identified a novel variant in a paralog of adiponectin (Adipoq), C1qtnf2, predicted
to be disruptive. C1qtnf2 is a ubiquitously expressed lipokine with similar function to adipo-
nectin. Adipoq has been shown to have anti-myeloma effects in KaLwRij mice and in humans
[12], and we confirmed significantly lower Adipoq expression in KaLwRij BMSCs. Together,
these results provide additional lines of evidence that multiple pathways and cell types are
Fig 4. KaLwRij bonemarrow stromal cells (BMSCs) have altered gene expression profiles
independent of Samsn1. (a) Microarray analysis of B6 and KaLwRij primary BMSCs. (b-d) RT-qPCR
analysis of Tnfrsf22, Tnfrsf23, Tnfrsf26, Adipoq, and Fstl4mRNA levels in B6 and KaLwRij BMSCs.
* P >0.05, ** P > 0.005, *** P < 0.0005.
doi:10.1371/journal.pone.0127828.g004
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involved in KaLwRij MM predisposition, and validate our combined genetics approach as a
method for identifying pathways involved in MM pathogenesis.
SAMSN1 expression is decreased in MGUS and MM patient samples (S3 Fig) and has re-
duced expression in human MM cell lines [11], but SAMSN1 is not the target of somatic muta-
tion in human MM [14]. Further work to map the SAMSN1 pathway in humans is needed
before we can determine the significance of SAMSN1 to human MM. While SAMSN1 is con-
served in humans, one of its murine binding partners, PIRB is not [18]. SAMSN1 is also re-
ported to bind cortactin, a component of integrin signaling and cell migration that is conserved
in humans [19], but it is not known whether this interaction is necessary for SAMSN1's role in
MM. We pursued investigation of the role of Samsn1 in KaLwRij mouse BIP susceptibility on
the basis of a SNP in the human SAMSN1 locus identified in a MM patient GWAS (Fig 2).
While SAMSN1 is not deleted in human MM, components of a SAMSN1 pathway appear likely
to involved in myeloma susceptibility and/or disease progression.
Our observation that the susceptible background of KaLwRij mice involves multiple cell
types helps explain two persistent dilemmas in the myeloma field: i) the marked clonal hetero-
geneity observed in human MM samples and ii) the inability of human MM cells to engraft in
immunocompromised mice without co-transplantation of myeloid and stromal cells [7]. Drug
resistance and MM cell survival is well-known to involve several stroma cell types, but the as-
sumption in the field has been that it is the malignant MM cells that subvert normal bone mar-
row cells to create a pro-tumor milieu. Our findings suggest for the first time that multiple cell
lineages are involved in MM pathogenesis prior to disease manifestation and independently of
tumor cell somatic mutations. Further evaluation of the interaction between somatic and germ-




The study cohort was approved by the Human Research Protection Office at Washington Uni-
versity School of Medicine and at the Mayo Clinic. Informed written consent from the patients
was obtained in accordance with the Declaration of Helsinki. Mice were housed in shared path-
ogen-free conditions according the guidelines of the Division of Comparative Medicine, Wash-
ington University School of Medicine. The Washington University Animal Studies Committee
approved all experiments.
Mice
129S1/SvImJ, A/J, AKR/J, BALB/cByJ, CBA/J, C3H/HeJ, C57BL/6, DBA/2J, FVB/NJ, NOD/
ShiLtJ, SJL/J, and NOD-scid–IL2Rγmice were purchased from The Jackson Laboratory.
C57Bl/KaLwRij mice were originally obtained from Gregory Mundy at Vanderbilt University.
Mice were housed in shared pathogen-free conditions according the guidelines of the Division
of Comparative Medicine, Washington University School of Medicine. Mice were euthanized
by asphyxiation using CO2 chambers. The animal ethics committee approved all experiments.
Samsn1-/- mice were originally obtained from Dingyan Wang [9]. Samsn1-/- and Samsn1+/+
mice were housed in shared pathogen-free conditions according to the guidelines from the An-
imal Resource Centre of the University Health Network, Princess Margaret Hospital Animal
Facility.
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Primary cell culture
Splenic B-cells were negatively selected via MACS with anti-CD43 beads (Miltenyi Biotec).
Cells were cultured in RPMI 1650 media, 10% FBS, 0.00035% BME, 1% penicillin-streptomy-
cin and stimulated with 10 ng/ml LPS and 20 ng/ml IL-4 for 72 hours. Cells were character-
ized by FACS (CD43- / B220+ / IgD+, S5 Fig). To generate bone marrow macrophages
(BMMs), whole bone marrow was cultured in αMEM, 10% FBS, 1% penicillin-streptomycin,
50 ng/ml MCSF for 3 days. Cells were characterized by FACS (GR1- / F4/80+, S7 Fig). Prolif-
eration was measured by standard MTT assay (Sigma-Aldrich). M2 polarized macrophages
were generated by stimulating BMMs with 5 ng/ml IL-4 for 24 hours. Bone marrow stromal
cells (BMSCs) were generated by plating whole bone marrow cells in ascorbic acid-free
αMEM, 10% FBS, 1% penicillin-streptomycin for 7 days in 5% oxygen followed by negative
selection via MACS with anti-CD45 beads (Miltenyi Biotec). Cells were characterized by
FACS (CD45-, S6 Fig). Flow Cytometric Analysis was performed using FACSCALIBUR (BD
Biosciences) and analyzed with FlowJo software (Tree Star). Antibodies used: APC-CD45 (BD
Pharmingen), FITC-Gr1 (eBioscience), APC-F4/80 (BioLegend), FITC-CD43 (BD Pharmin-
gen), APC-B220 (eBioscience), and PE-IgD (eBioscience).
5TGM1-GFP cell culture
The 5TGM1-GFP (5TGM1) cell line was originally obtained from Gregory Mundy at Vander-
bilt University. Samsn1 cDNA was subconed into an MSCV-PGK-Puro plasmid.
MSCV-PGK-Puro plasmid and lentiviral vectors pCMVΔ8.9 and pM2G were transfected into
HEK293T cells. Cell supernatant containing lentivirus was then plated on 5TGM1 cells and se-
lected with puromycin for 72 hours. Cells were maintained in DMEM, 10% FBS, 1% penicillin-
streptomycin. Proliferation was measured by BrdU ELISA (Roche Diagnostics).
Immunoblotting
Antibodies: SAMSN1 (Sigma-Aldrich), actin (Sigma-Aldrich), and GFP (Santa Cruz Biotech-
nology). Blots were incubated with horseradish conjugated secondary antibodies (GE Health-
care) and visualized by chemiluminescence (Pierce Biotechnology).
5TGM1 in vivo tumors
1x106 5TGM1 cells were injected subcutaneously into the right flank of NOD-scid-IL2Rγ fe-
male mice. 14 days following tumor inoculation, 0.8x106 ex vivo M2 polarized macrophages
were injected directly into the tumor. Tumor volume was monitored by bidirectional precision
caliper measurements (1/2 x length x width2). Maximum tumor volume was approximately
2cm3.
Gene expression microarrays
RNA was extracted from C57BL/6 and KaLwRij BMMs (3 mice/strain) and BMSCs (2 mice/
strain) using RNeasy Mini kit (Qiagen). RNA samples were submitted to the Genome Technol-
ogy Access Center at Washington University School of Medicine for hybridization using the
GeneChip Mouse Gene 1.0 ST array (Affymetrix). Differentially expressed genes were defined
as1.5 fold changed between C57BL/6 and KaLwRij.
We re-analyzed the microarray data of CD138+ plasma cells from healthy donors, MGUS
patients, and MM patients published by Fonseca, R. et al. (GSE6477) [20, 21].
Data was analyzed using Partek Genomics Suite (Partek Inc.).
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Quantitative reverse transcription PCR
RNA was extracted using RNeasy Mini kit (Qiagen) and cDNA generated using iScript (Bio-
Rad). Quantitative PCR was completed using SsoFast EVA Green Supermix or iQ Supermix
(Bio-Rad). All samples run with biological replicates of 2. Primer sequences are in S1
Methods.
Statistics
Data are shown as mean +/- SEM. Unless otherwise indicated, experiments were analyzed
using Student’s t-test to compare 2 groups or ANOVA to compare multiple groups. p<0.05;
p<0.01; p<0.001.
Supporting Information
S1 Fig. Immune responses are significantly different among mouse strains. Schema for im-
munization and serial serum sample protocol. Serum was collected at baseline (T0–5 months),
post-primary immunization (T1–7 months), post-boosting immunization (T2–8.5 months), 12
months (T3), and 18 months (T4). Analysis of serial serum samples by ELISA for (b) immuno-
globulin isotype G, (c) immunoglobulin isotype M, and (d) immunoglobulin isoype A. (e) Rep-
resentative SPEP of mouse serum samples negative (-) and positive (+) for M-spike.
(PDF)
S2 Fig. Samsn1 is deleted in KaLwRij and expression varies by cell type in C57BL/6. (a)
PCR amplification of the regions surrounding the 180kb deletion including Samsn1 identified
via WGS of the KaLwRij strain. Primers flanking the breakpoint amplified a product in KaL-
wRij genomic DNA and KaLwRij-derived 5TGM1 myeloma cell line DNA, but not C57BL/6
genomic DNA. (b) Samsn1mRNA expression was measured by RT-qPCR in multiple cell
types. CD43- B cells were analyzed pre- and post-stimulation for 72hrs with IL4 and LPS. Mac-
rophages were analyzed pre- and post-polarization to a M2 phenotype using IL4. CD45-
BMSCs were also analyzed for Samsn1 expression.  P< 0.005,  P< 0.0005.
(PDF)
S3 Fig. SAMSN1 is expressed at a lower level in human MGUS and MM plasma cells.Micro-
array data from CD138+ plasma cells from human healthy donors, MGUS patients, and MM
patients, first published by R. Fonseca et al. in 2006 (GEO accession: GSE6477) was analyzed
for SAMSN1 expression levels.  P< 0.05,  P> 0.0001.
(PDF)
S4 Fig. FACS analysis of splenic B-cells. Isolated mouse splenocytes were negatively selected
by magnetic immunodepletion, using anti-CD43 beads (Miltenyi Biotec). The negative fraction
was then analysed by FACS. The CD43− (middle panel) and naive B-cell (B220+, IgD+, right
panel) populations are shown.
(PDF)
S5 Fig. FACS analysis of bone marrow stromal cells.Whole bone marrow cells were cultured
ascorbic acid-free αMEM, 10% FBS, 1% penicillin-streptomycin for 7 days in 5% oxygen (left
panels, “pre-sorted”). On day 7, cells were negatively selected by MACS with anti-CD45 beads
(right panels).
(PDF)
S6 Fig. FACS analysis of bone marrow macrophages.Whole bone marrow was cultured in
αMEM, 10% FBS, 1% penicillin-streptomycin, 50 ng/ml MCSF for 3 days. After 3 days, the cell
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population is enriched for GR1- / F4/80+ macrophages.
(PDF)
S7 Fig. FACS analysis of bone marrow macrophages.Whole bone marrow was cultured in
αMEM, 10% FBS, 1% penicillin-streptomycin, 50 ng/ml MCSF for 3 days. After 3 days, the cell
population is enriched for GR1- / F4/80+ macrophages.
(PDF)
S1 Methods. Supplemental section with expanded details regarding the experimental meth-
ods used in this manuscript.
(DOCX)
S1 Table. Mice with positive M-spike on serum protein electrophoresis.
(XLSX)
S2 Table. Candidate genes underlying genetic susceptibility to BIP in KaLwRij mice.
(XLSX)
S3 Table. Candidate genes underlying genetic susceptibility to multiple myeloma in hu-
mans.
(XLSX)
S4 Table. KaLwRij germline structural variants.
(XLSX)
S5 Table. KaLwRij germline SNVs.
(XLSX)
S6 Table. KaLwRij germline Indels.
(XLSX)
S7 Table. Frameshift and splice site mutations in the KaLwRij germline.
(DOCX)
S8 Table. Microarray analysis of BMM and BMSC gene expression.
(XLSX)
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